Pmda - Pharmaceuticals and Medical Devices Agency
Menu
Close

Regulatory Science/The Science Board/Standard Development

Pediatric Drugs WG

About this WG

This WG organizes the points at issues over pediatric drugs and investigate the measures for expediting the review as well as encouraging their development through the exchange of information with overseas relevant organizations.

Our Task

  • Encourage industries and investigators to develop medicinal products for children
  • Strengthen collaboration with foreign regulatory agencies for development of pediatric medicines
  • Studying and organizing past reviews and cases of consultations
  • Exchanging views with domestic stakeholders (medical institutions, industry groups)

Established

November, 2011

Members

Office of New Drug I to V
Office of Cellular and Tissue-based Products
Office of Vaccines and Blood Products
Office of Pharmacovigilance I to II
Office of Regulatory Science Coordination

Related Notification

March 29, 2024
PSB/PED Notification No. 0329-1

March 29, 2024
Administrative Notice

January 16, 2024
PSB/PED Notification No. 0116-3

January 12, 2024
PSB/PED Notification No. 0112-3

November 26, 2020
Administrative Notice

August 31, 2020
PSEHB/PED Notification No. 0831-5

August 31, 2020
PSEHB Notification No. 0831-11

Past Presentations (Last 5 years)

First Exchange Meeting on Facilitating R&D and Scientific Supervision for Pediatric Drugs in China, Web, June 2022

 

Joint EFGCP/DIA Conference “Better Medicines for Children”, Web, October 2021

 

17th Annual Meeting DIA Japan 2020, Web, September 2020

 

17th Annual Meeting DIA Japan 2020, Web, September 2020

 

16th Annual Meeting, DIA Japan 2019, Tokyo, Japan, November 2019